On February 13thth, Eevia Health Plc (publ) (“Eevia”) announced that the Company has initiated a EUR...
Redeye comments in Invisio’s Q4-results which were in line with the preannounced results.
Rec PTP -1% vs ABGSCe, driven by lower rental income Values largely unchanged, despite slight yield ...
Endomines successfully capitalized on the increased gold market prices during the second half of the...
Finnair’s Q4 top line and profitability came in above estimates as ticket pricing pressure already e...
Raute’s Q4 margins were a bit lower than we estimated even if top line was higher than we expected.
CapMan’s Q4 results came with a pleasant surprise through higher than anticipated investment returns...
Q4: EBITDA of NOK 5m vs ABGSCe NOK 6m Lower target range likely Estimates likely unchanged Q4: EBIT...
Redeye provides its initial take on Mentice’s Q4 2024 report, which came in below our estimates.
Redeye comments on a solid Q4 report in a soft market, showing that CombinedX is back among the qual...
Sales -10% vs. ABGSCe, but EBIT only -2% on better opex control GC&MP to continue growth; NW&FT, FW ...
Q4 sales -1% below our ests. at SEK 229m, for 12.5% org.
Över lag var kvartalet en miss och resultatet kom in klart lägre än vår prognos.
Q4-rapporten kom in i med våra prognoser efter vinstvarningen.
Redeye is encouraged by the new MOU, highlighting the shift from technology discussions to preparati...
Redeye is encouraged by the upbeat Q4 report showing solid top-line numbers and a small profit on EB...
Sprint Bioscience delivered Q4 sales within the recent range at SEK 16.
Redeye comments on Fortnox’s Q4 report, showing underlying numbers largely matching our expectations...
Redeye provides its initial take on Acarix’s Q4 report, which showed revenues falling c32% short of ...
ExpreS2ion Biotechnologies har påbörjat screening av deltagare i bolagets fas 1-studie med vaccinkan...
